Overview

A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Determine the relapse-free survival of resected pancreatic cancer patients following two novel regimens with activity in advanced disease.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Treatments:
Albumin-Bound Paclitaxel
Folfirinox
Gemcitabine
Paclitaxel